News
Parkinson’s UK partners with UCL on phase II trial
Parkinson’s UK has partnered with University College London (UCL) and will invest £1m in a phase II clinical trial to investigate if the drug ondansetron can alleviate hallucinations in people with Parkinson’s disease.